Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity

Nature Cell Biology

Volumn 18, Issue 7, 2016, Pages 790-802

  Baer, Caroline ^a,c   Squadrito, Mario Leonardo ^a,c   Laoui, Damya ^a   Thompson, Danielle ^a   Hansen, Sarah K ^a   Kiialainen, Anna ^b   Hoves, Sabine ^c   Ries, Carola H ^c   Ooi, Chia Huey ^b,c   De Palma, Michele ^a  

^a EPFL   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DICER; GAMMA INTERFERON; MICRORNA; MICRORNA LET 7; RNA; STAT1 PROTEIN; UNCLASSIFIED DRUG; DEAD BOX PROTEIN; DICER1 PROTEIN, MOUSE; MIRNLET7 MICRORNA, MOUSE; RIBONUCLEASE III;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL ASSAY; CELL POLARITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DICER GENE; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GENE DELETION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYSOZYME M CRE GENE; MACROPHAGE ACTIVATION; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; ANIMAL; CELL CULTURE; DEFICIENCY; GENETICS; IMMUNOLOGY; MACROPHAGE; METABOLISM; NEOPLASM; TUMOR MICROENVIRONMENT;

ANIMALS; CELLS, CULTURED; DEAD-BOX RNA HELICASES; HUMANS; INTERFERON-GAMMA; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICRORNAS; NEOPLASMS; RIBONUCLEASE III; TUMOR MICROENVIRONMENT;

EID: 84976516808     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb3371     Document Type: Article

References (70)

1. Wynn T. A, Chawla A, & Pollard J. W. Macrophage biology in development, homeostasis and disease. Nature 496, 445-455 (2013).
2. Noy R, & Pollard J. W. Tumor-Associated macrophages: from mechanisms to therapy. Immunity 41, 49-61 (2014).
3. Lahmar Q, et al. Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment. Biochim. Biophys. Acta 1865, 23-34 (2016).
4. Heusinkveld M, & van der Burg S. H. Identification and manipulation of tumor associated macrophages in human cancers. J. Trans. Med. 9, 216 (2011).
5. Biswas S. K, & Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889-896 (2010).
6. Sica A, & Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787-795 (2012).
7. Pucci F, et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood resident monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 114 901-914 (2009).
8. Movahedi K, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70, 5728-5739 (2010).
9. Squadrito M. L, et al. miR-511-3p modulates genetic programs of tumor-Associated macrophages. Cell Rep. 1, 141-154 (2012).
10. Duluc D, et al. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-Associated macrophages. Int. J. Cancer 125, 367-373 (2009).
11. Kratochvill F, et al. TNF counterbalances the emergence of M2 tumor macrophages. Cell Rep. 12, 1902-1914 (2015).
12. Guiducci C, Vicari A. P, Sangaletti S, Trinchieri G, & Colombo M. P. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65, 3437-3446 (2005).
13. De Palma M, et al. Tumor-targeted interferon-Alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 14, 299-311 (2008).
14. Rolny C, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19, 31-44 (2011).
15. Pyonteck S. M, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264-1272 (2013).
16. Ha M, & Kim V. N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15, 509-524 (2014).
17. Bernstein E, et al. Dicer is essential for mouse development. Nat. Genet. 35, 215-217 (2003).
18. Park C. Y., et al. A resource for the conditional ablation of microRNAs in the mouse. Cell Rep. 1, 385-391 (2012).
19. Park C. Y, Choi Y. S, & McManus M. T. Analysis of microRNA knockouts in mice. Hum. Mol. Genet. 19, R169-175 (2010).
20. Squadrito M. L, et al. Endogenous RNAs modulate microRNA sorting to exosomes and transfer to acceptor cells. Cell Rep. 8, 1432-1446 (2014).
21. Graff J. W, Dickson A. M, Clay G, McCaffrey A. P, & Wilson M. E. Identifying functional microRNAs in macrophages with polarized phenotypes. J. Biol. Chem. 287, 21816-21825 (2012).
22. Bleckmann A, et al. Integrated miRNA and mRNA profiling of tumor-educated macrophages identifies prognostic subgroups in estrogen receptor-positive breast cancer. Mol. Oncol. 9, 155-166 (2015).
23. Squadrito M. L, Etzrodt M, De Palma M, & Pittet M. J. MicroRNA-mediated control of macrophages and its implications for cancer. Trends Immunol. 34, 350-359 (2013).
24. Sonda N, et al. miR-142-3p prevents macrophage differentiation during cancerinduced myelopoiesis. Immunity 38, 1236-1249 (2013).
25. Zonari E, et al. A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. Blood 122 243-252 (2013).
26. Xu S, et al. Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma. J. Natl Cancer Inst. 106 (2014).
27. Clausen B. E, Burkhardt C, Reith W, Renkawitz R, & Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8, 265-277 (1999).
28. Harfe B. D, McManus M. T, Mansfield J. H, Hornstein E, & Tabin C. J. The RNaseIII enzyme Dicer is required for morphogenesis but not patterning of the vertebrate limb. Proc. Natl Acad. Sci. USA 102, 10898-10903 (2005).
29. Muzumdar M. D, Tasic B, Miyamichi K, Li L, & Luo L. A global doublefluorescent Cre reporter mouse. Genesis 45 593-605 (2007).
30. De Palma M, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211-226 (2005).
31. Coffelt S. B, et al. Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. J. Immunol. 186, 4183-4190 (2011).
32. Ries C. H, et al. Targeting tumor-Associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25, 846-859 (2014).
33. Lin E. Y, Nguyen A. V, Russell R. G, & Pollard J. W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727-740 (2001).
34. Mullokandov G, et al. High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries. Nat. Methods 9, 840-846 (2012).
35. Lewis B. P, Burge C. B, & Bartel D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15-20 (2005).
36. Eichhorn S. W, et al. mRNA destabilization is the dominant effect of mammalian microRNAs by the time substantial repression ensues. Mol. Cell 56, 104-115 (2014).
37. Ooi C. H, et al. A densely interconnected genome-wide network of microRNAs and oncogenic pathways revealed using gene expression signatures. PLoS Genet. 7 e1002415 (2011).
38. Yang J. S, et al. Conserved vertebrate mir-451 provides a platform for Dicerindependent, Ago2-mediated microRNA biogenesis. Proc. Natl Acad. Sci. USA 107, 15163-15168 (2010).
39. Viswanathan S. R, Daley G. Q, & Gregory R. I. Selective blockade of microRNA processing by Lin28. Science 320, 97-100 (2008).
40. Gilfillan S, et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J. Exp. Med. 205, 2965-2973 (2008).
41. Freeman G. J, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
42. Topalian S. L, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
43. Vonderheide R. H, & Glennie M. J. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19, 1035-1043 (2013).
44. Pardoll D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
45. Yona S, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38, 79-91 (2013).
46. Guo S, et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proc. Natl Acad. Sci. USA 107, 14229-14234 (2010).
47. Alemdehy M. F, et al. Dicer1 deletion in myeloid-committed progenitors causes neutrophil dysplasia and blocks macrophage/dendritic cell development in mice. Blood 119, 4723-4730 (2012).
48. Mizoguchi F, et al. Osteoclast-specific Dicer gene deficiency suppresses osteoclastic bone resorption. J. Cell. Biochem. 109, 866-875 (2010).
49. Kuipers H, Schnorfeil F. M, Fehling H. J, Bartels H, & Brocker T. Dicerdependent microRNAs control maturation, function, and maintenance of Langerhans cells in vivo. J. Immunol. 185, 400-409 (2010).
50. Ikeda H, Old L. J, & Schreiber R. D. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13, 95-109 (2002).
51. Ellis S. L, et al. The cell-specific induction of CXC chemokine ligand 9 mediated by IFN-gamma in microglia of the central nervous system is determined by the myeloid transcription factor PU.1. J. Immunol. 185, 1864-1877 (2010).
52. Tannenbaum C. S, et al. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. 161, 927-932 (1998).
53. Harlin H, et al. Chemokine expression in melanoma metastases associated with CD8C T-cell recruitment. Cancer Res. 69, 3077-3085 (2009).
54. De Palma M, & Lewis C. E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23, 277-286 (2013).
55. Coffelt S. B, & de Visser K. E. Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends Immunol. 36, 198-216 (2015).
56. Ries C. H, Hoves S, Cannarile M. A, & Ruttinger D. CSF-1/CSF-1R targeting agents in clinical development for cancer therapy. Curr. Opin. Pharmacol. 23, 45-51 (2015).
57. Curtale G, et al. Negative regulation of Toll-like receptor 4 signaling by IL-10-dependent microRNA-146b. Proc. Natl Acad. Sci. USA 110, 11499-11504 (2013).
58. Cobos Jimenez V, et al. Next-generation sequencing of microRNAs uncovers expression signatures in polarized macrophages. Physiol. Genomics 46, 91-103 (2014).
59. Banerjee S, et al. MicroRNA let-7c regulates macrophage polarization. J. Immunol. 190, 6542-6549 (2013).
60. Mathsyaraja H, et al. CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth. Oncogene 34, 3651-3661 (2015).
61. Chen X. M, Splinter P. L, O?Hara S. P, & LaRusso N. F. A cellular micro-RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection. J. Biol. Chem. 282, 28929-28938 (2007).
62. Teng G. G, et al. Let-7b is involved in the inflammation and immune responses associated with Helicobacter pylori infection by targeting Toll-like receptor 4. PLoS ONE 8, e56709 (2013).
63. O? Neill L. A, Sheedy F. J, & McCoy C. E. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat. Rev. Immunol. 11, 163-175 (2011).
64. Amendola M, Venneri M. A, Biffi A, Vigna E, & Naldini L. Coordinate dualgene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat. Biotechnol. 23, 108-116 (2005).
65. De Palma M, & Naldini L. Transduction of a gene expression cassette using advanced generation lentiviral vectors. Methods Enzymol. 346, 514-529 (2002).
66. Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676-682 (2012).
67. Langmead B, & Salzberg S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357-359 (2012).
68. Mortazavi A, Williams B. A, McCue K, Schaeffer L, & Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5, 621-628 (2008).
69. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074 (2013).
70. Sandmann T, Kummerfeld S. K, Gentleman R, & Bourgon R. gCMAP: userfriendly connectivity mapping with R. Bioinformatics 30, 127-128 (2014).